Minerva神经科学 NERV 深 沪
已收盘 10-31 16:00:00 美东时间
4.20
+0.160
+3.96%
华盛通- 最 高4.30
- 今 开4.01
- 成交量 9.94万股
- 最 低 4.01
- 昨 收 4.04
- 总市值 2937.23万
- 52周最高 12.46
- 市盈率 静 22.11
- 换手率 1.42%
- 52周最低 1.15
- 委 比 29.46%
- 总股本 699.34万
- 历史最高 126.72
- 量 比 0.21
- 振 幅 7.18%
- 历史最低 1.15
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Minerva Neurosciences Secures $200M for Drug Trials
The latest update is out from Minerva Neurosciences ( ($NERV) ). On October 21,...
10-22 18:28
Minerva Neurosciences shares are trading higher after the company announced financing of up to $200 million to advance Roluperidone for schizophrenia.
Minerva Neurosciences shares are trading higher after the company announced fin...
10-21 20:03
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences, Inc. has raised up to $200 million to advance the Phase 3 trial of roluperidone for treating negative symptoms of schizophrenia. The proceeds, including $80 million upfront and additional $80 million via Tranche A warrants, will fund the confirmatory trial and NDA resubmission. Up to $40 million more could be received from Tranche B warrants upon milestone achievements. Three new directors with schizophrenia trial experienc...
10-21 12:00
美参议院否决政府拨款法案 联邦政府或将停摆 | 环球市场
①美国会预算办公室：政府停摆期间每天约75万联邦雇员被迫休假；②美联储古尔斯比：政府停摆对经济的影响取决于停摆的范围和持续时间；③卡塔尔首相：将与土埃和哈马斯就美方“20点计划”进行讨论；④OPEC+代表：将考虑在未来三个月加大增产力度。
10-01 07:22
Minerva Neurosciences shares are trading higher after the company reported a Q2 EPS beat.
Minerva Neurosciences shares are trading higher after the company reported a Q2...
08-15 04:54
Minerva Neurosciences Q2 EPS $(0.43) Beats $(0.90) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.90) by 52.22 percent. This is a 60.55 percent increase over losses of $(1.09) per share
08-15 04:37
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Minerva Neurosciences announced that the FDA has confirmed the need for an additional confirmatory clinical trial for roluperidone to address deficiencies cited in a previous Complete Response Letter. The trial will focus on patients with schizophrenia experiencing negative symptoms and stable positive symptoms, requiring a double-blind, single-dose regimen with a 12-week primary endpoint assessing changes in negative symptoms. The company also e...
08-14 20:35
Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. announced it will release its second quarter 2025 financial and operating results before market open on August 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be available via webcast and phone. Neuronetics, a leader in neurohealth solutions, specializes in the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for depression and anxiety when traditional medications fail.
07-22 12:30
必胜客×新世纪福音战士：二搭同步率100%味觉补完计划
近日，EVA主题巨型机体装置空降上海、杭州和广州三城必胜客门店，标志性紫色涂装的初号机、红色涂装的2号机以及深度还原的驾驶舱格外醒目，引得路人纷纷驻足打卡...
04-29 20:27
Minerva Neurosciences Reports Improved 2024 Financials
Minerva Neurosciences ( ($NERV) ) has released its Q4 earnings. Here is a break...
03-06 12:14
